Trial reportJournal of consulting and clinical psychology2015
Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
Trial report in Journal of consulting and clinical psychology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- Predictors of clinical worsening during a discontinuation trial of serotonin reuptake inhibitors for obsessive compulsive disorder.Journal of anxiety disorders · 2024Trial
- Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder.Depression and anxiety · 2018Trial
- Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes well?Behaviour research and therapy · 2016Trial
- Predictors of dropout in concurrent treatment of posttraumatic stress disorder and alcohol dependence: Rate of improvement matters.Behaviour research and therapy · 2016Trial
- Predictors of EX/RP alone versus EX/RP with medication for adults with OCD: does medication status moderate outcomes?Journal of obsessive-compulsive and related disorders · 2023Article
- Identifying trajectories of symptom change in adults with obsessive compulsive disorder receiving exposure and response prevention therapy.Journal of anxiety disorders · 2023Article
- Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder.Behaviour research and therapy · 2021Article
- Innovations in the Delivery of Exposure and Response Prevention for Obsessive-Compulsive Disorder.Current topics in behavioral neurosciences · 2021Article
- Do polygenic risk and stressful life events predict pharmacological treatment response in obsessive compulsive disorder? A gene-environment interaction approach.Translational psychiatry · 2019Article
- Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders.Drugs in R&D · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
objectivePatients with obsessive-compulsive disorder (OCD) often only partially respond to serotonin reuptake inhibitors (SRIs). In such cases, American Psychiatric Association practice guidelines suggest augmenting SRIs with cognitive-behavioral therapy consisting of exposure and ritual prevention (EX/RP) or antipsychotic medication (i.e., risperidone). We examined moderators and predictors of these 2 augmentation strategies.
methodData came from a randomized controlled trial that compared adding EX/RP or risperidone to SRIs in adults with OCD. Patients entered the study on a stable SRI dosage and were randomized to EX/RP (N = 40), risperidone (N = 40), or placebo (N = 20). Data were analyzed using multilevel modeling.
resultsPretreatment OCD severity, age, and depression were significant moderators. Although OCD severity was unrelated to EX/RP response, individuals with more severe OCD had poorer outcomes and slower improvement with risperidone. Increasing age predicted better response to risperidone, but not EX/RP. Increased depression predicted poorer response to placebo, but not EX/RP or risperidone. Poorer functioning predicted worse outcome across all 3 conditions. Together, these moderators and predictor accounted for 33% of the variance in outcomes, above and beyond the 30.8% accounted for by treatment condition.
conclusionsSRI augmentation with EX/RP was more effective than risperidone across all of the demographic and clinical variables tested. EX/RP's superiority over risperidone increased with baseline OCD severity and with younger age. These data indicate that EX/RP should be the recommended SRI augmentation strategy, even for severe OCD. What determines the degree of EX/RP response in individual patients deserves further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.